Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482028 | 0.84 | ADORA1 (0.56) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL10413878 | 0.84 | ADORA1 (0.48) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL22482231 | 0.80 | ADORA1 (0.45) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL22482230 | 0.79 | ADORA1 (0.39) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL22482286 | 0.78 | ADORA1 (0.37) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL6425010 | 0.74 | ADORA1 (0.55) | ADORA1ESR2NR1H2MAPTKDM4E | |
| SCHEMBL27244463 | 0.74 | ADORA1 (0.46) | ADORA1ESR2NR1H2MAPTP2RX3 | |
| SCHEMBL2576275 | 0.74 | ADORA1 (0.46) | ADORA1ESR2NR1H2MAPTUSP2 | |
| SCHEMBL4792110 | 0.74 | ADORA1 (0.46) | ADORA1ESR2NR1H2MAPK1 | |
| SCHEMBL4091052 | 0.73 | ADORA1 (0.82) | ADORA1ESR2NR1H2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ADORA1 3877/4885ESR2 1630/4885NR1H2 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.